Potential Harmful Effects of Discontinuing ACE-inhibitors and ARBs in COVID-19 Patients

eLife - United Kingdom
doi 10.7554/elife.57278
Full Text
Abstract

Available in full text

Date
Authors
Publisher

eLife Sciences Publications, Ltd

Related search

Should ACE Inhibitors and Angiotensin Receptor Blockers Be Withdrawn in the Current Setting of COVID-19 Infection?

Wits Journal of Clinical Medicine
2020English

Telmisartan: The ACE of ARBs?

Hypertension
Internal Medicine
2006English

Angiotensin-Converting Enzyme Inhibitors (ACE-Is) Versus Angiotensin- Receptor Blockers (ARBs): Any Superiority?

Journal of Hypertension- Open Access
2012English

Transmission Potential of COVID-19 in Iran

2020English

Potential Neurological Symptoms of COVID-19

Therapeutic Advances in Neurological Disorders
NeurologyPharmacology
2020English

ACE Inhibitors and AT1R Blockers for COVID-2019: Friends or Foes ?

2020English

Dual Blockade of the Renin-Angiotensin System With Angiotensin Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers (ARBs)

British Journal of Clinical Pharmacology
Pharmacology
2011English

Venous Thromboembolism in COVID-19 Patients

Journal of Thrombosis and Haemostasis
MedicineHematology
2020English

Mechanism of Thrombocytopenia in COVID-19 Patients

Annals of Hematology
MedicineHematology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy